Offers exceptional visualization within the surgical cavity, for precision and safety
LAS VEGAS, April 27, 2017 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ:IVTY), an advanced surgical illumination company focused on minimal access surgery, today at the 18th American Society of Breast Surgeons annual scientific conference, announced the introduction of PhotonBlade™, a dynamic precision illuminator with enhanced energy delivery.
PhotonBlade represents an entirely new category of Intelligent Photonics®, delivering directed, thermally cool illumination at the precise point of surgical treatment. Further, PhotonBlade’s novel energy platform consists of a proprietary shielded blade for precise cutting and coagulation of tissue, with minimal collateral effect. This sophisticated illumination technology further allows for unique use in a fluid filled environment and does not require a proprietary generator, thereby leveraging widely available operating room equipment and avoiding an institutional capital investment.
"We are very proud and excited with the introduction of PhotonBlade,” stated Philip Sawyer, President and CEO of Invuity. “We collaborated with some of the top surgeons in the country on its unique design, which was created for more visualization and precision of the surgical field. This continues our strategic intention to create entirely new categories of intelligent photonics. The advanced illumination coupled with state-of-the-art energy delivery positions us solidly in an initially estimated $300 million available market for this technology,” continued Sawyer. “This demonstrates Invuity’s commitment to improving surgical treatment options and positively impacting patient lives.”
Dr. Rache Simmons, Chief of Breast Surgery at New York Presbyterian Weill Cornell Medical Center said, “The high-quality, point-of-treatment illumination of PhotonBlade coupled with precise energy delivery provides me with the optimal tool I need to perform oncologically effective procedures through small, remote incisions. Specifically, the intracavity illumination enables me to precisely tunnel deep within a breast cavity to remove some or all of the breast tissue from an incision that can be hidden. Ultimately, this contributes to improved survivorship for my patients, which after removing the cancer, is my number one priority.”
Invuity, Inc. is a leading medical technology company focused on developing and marketing advanced surgical devices to improve the ability of physicians to perform minimal access surgery through smaller and hidden incisions. The company's proprietary Intelligent Photonics™ technology delivers enhanced visualization which facilitates surgical precision, efficiency and safety. In addition, the company utilizes comprehensive strategic marketing programs to create stronger institutional partnerships. Clinical applications include women’s health, encompassing breast cancer and breast reconstruction surgery, gynecology and thyroid surgery. Additional applications include procedures for electrophysiology, spine, orthopedic, cardiothoracic, and general surgery. Invuity is headquartered in San Francisco, CA. For more information, visit www.invuity.com.
This announcement contains forward-looking statements that involve risks and uncertainties, including statements regarding financial projections for 2017, future product introductions, future sales and marketing initiatives, and market opportunities. Actual results could differ materially from those projected in the forward-looking statements as a result of certain risk factors, including, but not limited to: fluctuations in demand or failure to gain market acceptance for the Company's devices; the Company's ability to demonstrate to and gain approval from hospitals to use the Company's devices; the highly competitive business environment for surgical medical devices; the Company's ability to sell its devices at prices that support its current business strategies; difficulty forecasting future financial performance; protection of the Company's intellectual property; and compliance with necessary regulatory clearances or approvals. The Company undertakes no obligation to update the forward-looking information in this release. More information about potential factors that could affect the Company's business and financial results is included in its filings with the Securities and Exchange Commission, including, without limitation, under the captions: "Management's Discussion and Analysis of Financial Condition and Results of Operations," and "Risk Factors," which are on file with the Securities and Exchange Commission.
Commercial Marketing & Business Development
Investors & Media: